Treatment of metastatic uveal melanoma with intravenous fotemustine

Francesco Spagnolo, Marco Grosso, Virginia Picasso, Elena Tornari, Marianna Pesce, Paola Queirolo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The purpose of the present study was to retrospectively evaluate the safety and activity of intravenous fotemustine in patients with metastatic uveal melanoma. We report on a series of 25 consecutive patients diagnosed with metastatic uveal melanoma. Fotemustine was administered intravenously as a first-line treatment to all patients. Thrombocytopenia and leukopenia (any grade) were observed in 60 and 52% of patients, respectively. Only two patients discontinued treatment because of toxicity (G3 thrombocytopenia), whereas all other patients were discontinued for progressive disease. Two partial responses were observed. Nine patients had stable disease (disease control rate=44%). The median survival duration was 13.9 months, and the 1-year survival rate was 60%. Intravenous fotemustine is well tolerated and could improve the outcome of metastatic uveal melanoma patients with or without liver involvement, although a randomized prospective trial is required to confirm these results.

Original languageEnglish
Pages (from-to)196-198
Number of pages3
JournalMelanoma Research
Volume23
Issue number3
DOIs
Publication statusPublished - Jun 2013

Fingerprint

fotemustine
Therapeutics
Thrombocytopenia
Uveal melanoma
Leukopenia

Keywords

  • fotemustine
  • metastatic melanoma
  • uveal melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Dermatology

Cite this

Treatment of metastatic uveal melanoma with intravenous fotemustine. / Spagnolo, Francesco; Grosso, Marco; Picasso, Virginia; Tornari, Elena; Pesce, Marianna; Queirolo, Paola.

In: Melanoma Research, Vol. 23, No. 3, 06.2013, p. 196-198.

Research output: Contribution to journalArticle

Spagnolo, F, Grosso, M, Picasso, V, Tornari, E, Pesce, M & Queirolo, P 2013, 'Treatment of metastatic uveal melanoma with intravenous fotemustine', Melanoma Research, vol. 23, no. 3, pp. 196-198. https://doi.org/10.1097/CMR.0b013e3283610586
Spagnolo, Francesco ; Grosso, Marco ; Picasso, Virginia ; Tornari, Elena ; Pesce, Marianna ; Queirolo, Paola. / Treatment of metastatic uveal melanoma with intravenous fotemustine. In: Melanoma Research. 2013 ; Vol. 23, No. 3. pp. 196-198.
@article{e2e9be431efd44c1a2d99d681c7b3875,
title = "Treatment of metastatic uveal melanoma with intravenous fotemustine",
abstract = "The purpose of the present study was to retrospectively evaluate the safety and activity of intravenous fotemustine in patients with metastatic uveal melanoma. We report on a series of 25 consecutive patients diagnosed with metastatic uveal melanoma. Fotemustine was administered intravenously as a first-line treatment to all patients. Thrombocytopenia and leukopenia (any grade) were observed in 60 and 52{\%} of patients, respectively. Only two patients discontinued treatment because of toxicity (G3 thrombocytopenia), whereas all other patients were discontinued for progressive disease. Two partial responses were observed. Nine patients had stable disease (disease control rate=44{\%}). The median survival duration was 13.9 months, and the 1-year survival rate was 60{\%}. Intravenous fotemustine is well tolerated and could improve the outcome of metastatic uveal melanoma patients with or without liver involvement, although a randomized prospective trial is required to confirm these results.",
keywords = "fotemustine, metastatic melanoma, uveal melanoma",
author = "Francesco Spagnolo and Marco Grosso and Virginia Picasso and Elena Tornari and Marianna Pesce and Paola Queirolo",
year = "2013",
month = "6",
doi = "10.1097/CMR.0b013e3283610586",
language = "English",
volume = "23",
pages = "196--198",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Treatment of metastatic uveal melanoma with intravenous fotemustine

AU - Spagnolo, Francesco

AU - Grosso, Marco

AU - Picasso, Virginia

AU - Tornari, Elena

AU - Pesce, Marianna

AU - Queirolo, Paola

PY - 2013/6

Y1 - 2013/6

N2 - The purpose of the present study was to retrospectively evaluate the safety and activity of intravenous fotemustine in patients with metastatic uveal melanoma. We report on a series of 25 consecutive patients diagnosed with metastatic uveal melanoma. Fotemustine was administered intravenously as a first-line treatment to all patients. Thrombocytopenia and leukopenia (any grade) were observed in 60 and 52% of patients, respectively. Only two patients discontinued treatment because of toxicity (G3 thrombocytopenia), whereas all other patients were discontinued for progressive disease. Two partial responses were observed. Nine patients had stable disease (disease control rate=44%). The median survival duration was 13.9 months, and the 1-year survival rate was 60%. Intravenous fotemustine is well tolerated and could improve the outcome of metastatic uveal melanoma patients with or without liver involvement, although a randomized prospective trial is required to confirm these results.

AB - The purpose of the present study was to retrospectively evaluate the safety and activity of intravenous fotemustine in patients with metastatic uveal melanoma. We report on a series of 25 consecutive patients diagnosed with metastatic uveal melanoma. Fotemustine was administered intravenously as a first-line treatment to all patients. Thrombocytopenia and leukopenia (any grade) were observed in 60 and 52% of patients, respectively. Only two patients discontinued treatment because of toxicity (G3 thrombocytopenia), whereas all other patients were discontinued for progressive disease. Two partial responses were observed. Nine patients had stable disease (disease control rate=44%). The median survival duration was 13.9 months, and the 1-year survival rate was 60%. Intravenous fotemustine is well tolerated and could improve the outcome of metastatic uveal melanoma patients with or without liver involvement, although a randomized prospective trial is required to confirm these results.

KW - fotemustine

KW - metastatic melanoma

KW - uveal melanoma

UR - http://www.scopus.com/inward/record.url?scp=84877042118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877042118&partnerID=8YFLogxK

U2 - 10.1097/CMR.0b013e3283610586

DO - 10.1097/CMR.0b013e3283610586

M3 - Article

C2 - 23624366

AN - SCOPUS:84877042118

VL - 23

SP - 196

EP - 198

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 3

ER -